EUCTR2017-002441-30-CZActive, not recruitingPhase 1
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients with Inadequate Response to Prior Preventive Treatments
Teva Branded Pharmaceutical Products R&D, Inc.0 sites838 target enrollmentStarted: November 15, 2017Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 838
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
Inclusion Criteria
- •a. The patient is capable of giving signed informed consent
- •b. Male or female patient aged 18 to 70 years, inclusive.
- •c. The patient has a diagnosis of migraine with onset at =50 years of age.
- •d. The patient is in good health in the opinion of the investigators as determined by medical history, physical examination, laboratory tests, and ECG.
- •e. Body weight greater than 45 kg and body mass index (BMI) within the range 17.5 to 34.9 kg/m2 (inclusive).
- •f. The patient has a history of migraine (according to ICHD-3 criteria [IHS 2013]) or clinical judgment suggests a migraine diagnosis (not better accounted for by another ICHD-3 diagnosis) for =12 months prior to screening.
- •g. The patient fulfills the following criteria for CM or EM in prospectively collected baseline information during the 28-day run-in period:
- •For patients with CM:
- •? - Headache occurring on =15 days
- •- On =8 days, fulfilling any of the following:
- •? ICHD-3 diagnostic criteria C and D for 1.1 Migraine without aura
- •? ICHD-3 criteria B and C for 1.2 Migraine with aura
- •? Probable migraine (a migraine subtype where only 1 migraine criterion is
- •? The patient used a triptan or ergot derivative to treat an established headache
- •For patients with EM:
- •-Headache occurring on =6 days but <15
- •-On =4 days, fulfilling any of the following:
- •? ICHD-3 diagnostic criteria C and D for 1.1 Migraine without aura
- •? ICHD-3 criteria B and C for 1.2 Migraine with aura
- •? Probable migraine (a migraine subtype where only 1 migraine criterion is
- •? The patient used a triptan or ergot derivative to treat an established headache
- •h. At the time of screening, the patient must have documented inadequate response to 2 to 4 classes of prior preventive migraine medications (as defined in Appendix H) within the past 10 years (in medical chart or by treating physician’s confirmation; see Appendix I for acceptable documentation of previous treatment failure). Inadequate response to prior preventive migraine medications (including valproic acid) is defined as: no clinically meaningful improvement per treating physician’s judgment, after at
- •least 3 months of therapy at a stable dose considered appropriate for migraine prevention according to accepted country guidelines, or when treatment has to be interrupted because of adverse events that made it intolerable for the patient, or the medication (as defined in Appendix H) is contraindicated or unsuitable for the prophylactic treatment of migraine for the patient. The 3- month period does not apply if the drug is intolerable or contraindicated. If onabotulinumtoxinA is the previous preventive medication, at least 2 sets of injections and 3 months must have
- •passed since the last set of injections prior to the screening visit.
- •i. The patient agrees not to initiate any preventive migraine medications (as defined in Appendix H) during the run-in period double-blind treatment periodand open-label period. At the screening visit, at least 5 half-lives of these medications must have passed since the patient has been on any migraine preve
Exclusion Criteria
- •a. At time of screening visit, patient is receiving any preventive migraine medications, regardless of the medical indication (as defined in Appendix H) for more than 5 days and expects to continue with these medications
- •b. Patient has received onabotulinumtoxinA for migraine or for any medical or cosmetic reasons requiring injections in the head, face, or neck during the 3 months before screening visit
- •c. Patient uses medications containing opioids (including codeine) or barbiturates (including butalbital/aspirin/caffeine [Fiorinal®, Actavis plc], butalbital/paracetamol/caffeine [Fioricet®, Cardinal Health], or any other combination containing butalbital) on more than 4 days during the run-in period for the treatment of migraine or for any other reason
- •d. Patient has used an intervention/device (eg, scheduled nerve blocks and transcranial magnetic stimulation) for migraine during the 2 months prior to screening
- •e. Patient uses triptans/ergots as preventive therapies for migraine
- •f. Patient uses non-steroidal anti-inflammatory drugs (NSAIDs) as preventive therapy for migraine on nearly daily basis for other indications. Note: Low dose aspirin (eg, 81 mg) used for cardiovascular disease prevention is allowed
- •g. Patient suffers from unremitting headaches, defined as having headaches for more than 80% of the time he/she is awake, and less than 4 days without headache per month. Daily headache is acceptable if patient has headaches 80% or less of the time he/she is awake on most days
- •h. Patient has a clinically significant hematological, cardiac, renal, endocrine, pulmonary, gastrointestinal, genitourinary, neurologic, hepatic, or ocular disease that, in opinion of investigator, could jeopardize or would compromise the patient’s ability to participate in this study
- •i. Evidence or medical history of clinically significant psychiatric issues that, in opinion of investigator, could jeopardize or would compromise patient’s ability to participate in this study including major depression, panic disorder, or generalized anxiety disorder, any suicide attempt in the past or suicidal ideation with a specific plan the past two years prior to screening or current suicidal ideation as measured by eC-SSRS
- •j. History of clinically significant cardiovascular disease or vascular ischemia (such as myocardial, neurological [e.g., cerebral ischemia], peripheral extremity ischemia, or other ischemic event) or thromboembolic events (arterial or venous thrombotic or embolic events), such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism
- •k. History of human immunodeficiency virus, tuberculosis, or chronic hepatitis B or C infection
- •l. Past or current history of cancer, except for appropriately treated non-melanoma skin carcinoma in last 5 years
- •m. Pregnant or lactating female patients or female patients who plan to become pregnant during the study
- •n. Participation in clinical study of a new chemical entity or a prescription medicine within 2 months before screening (or 3 months in case of biologics if the half-life of the biologics is unknown) or 5 half-lives, whichever is longer, or is currently participating in another study of an IMP (or medical device)
Investigators
Similar Trials
Unknown
Phase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-385 40 mg compared with Leuprorelin in the Treatment of Uterine Fibroidsterine fibroidJPRN-jRCT2080223074Takeda Pharmaceutical Company Limited288
Active, not recruiting
Phase 1
A clinical trial of TEV-48125 to evaluate long term safety, tolerability and efficacy for the Preventive Treatment of MigraineEpisodic and Chronic MigraineMedDRA version: 20.0 Level: LLT Classification code 10066636 Term: Chronic migraine System Organ Class: 100000004852MedDRA version: 20.0 Level: LLT Classification code 10027602 Term: Migraine headache System Organ Class: 100000004852EUCTR2015-004550-18-FITeva Branded Pharmaceutical Products R&D, Inc.1,890
Active, not recruiting
Not Applicable
A Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple SclerosisEUCTR2008-006333-27-EEBiogen Idec Limited1,500
Active, not recruiting
Phase 1
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Crohn's DiseaseCrohn's DiseaseEUCTR2020-004775-40-LVArena Pharmaceuticals Inc.1,265
Active, not recruiting
Phase 1
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Patients Who Did Not Respond to Prior Preventive Migraine Treatmentsepisodic and chronic migraineMedDRA version: 20.0Level: HLTClassification code 10027603Term: Migraine headachesSystem Organ Class: 100000004852EUCTR2017-002441-30-SETeva Branded Pharmaceutical Products R&D, Inc.838